AstraZeneca has said that its Covid-19 vaccine offers “strong” protection among adults across ages in a US study that is long anticipated. This finding could aid rebuild public confidence in the Covid-19 vaccine shot worldwide, besides a move that is seen to be closer to clearance in the US.
The vaccine was 79% effective at preventing symptomatic cases of Covid-19. This includes older adults. According to the study, there was absence of severe illnesses or hospitalisations among volunteers who administered with the vaccine, in comparison to five such cases wherein participants received dummy shots, including a tiny number, nevertheless consistent with findings from various countries that the vaccine protects against the worst of the disease. The study was conducted among 30,000 people.
“I do hope it puts to bed any doubts about the vaccine efficacy. Overall where the vaccine is being used, it’s been shown to be highly effective. So I hope that the US study now will continue to give the vaccine some momentum and get it used even further around the world,” Mene Pangalos, AstraZeneca’s bio pharmaceuticals research chief told The Associated Press.